<DOC>
	<DOCNO>NCT00031811</DOCNO>
	<brief_summary>RATIONALE : Raloxifene exercise may improve bone health quality life breast cancer survivor . Assessing bone health quality life may improve ability plan treatment . PURPOSE : Randomized clinical trial study effectiveness raloxifene without exercise compare exercise alone woman previously treat breast cancer .</brief_summary>
	<brief_title>Raloxifene With Without Exercise Compared With Exercise Alone Women Who Have Been Previously Treated Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect raloxifene without exercise versus exercise alone bone reabsorption rate , bone formation rate , bone density woman previously treat breast cancer . - Determine effect regimens quality life patient . OUTLINE : This randomize , placebo-controlled , multicenter study . Patients randomize one four treatment arm . - Arm I : Patients ask exercise 5 day week instruction . Patients also receive oral placebo daily . - Arm II : Patients receive oral raloxifene daily . - Arm III : Patients ask exercise arm I . Patients also receive oral raloxifene daily . - Arm IV : Patients receive oral placebo daily . All patient receive oral calcium supplement daily . Treatment continue arm 24 month absence disease progression unacceptable toxicity . Quality life assess baseline every 3 month study . PROJECTED ACCRUAL : A total 240 patient ( 60 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer No metastatic disease At least 3 month 1 year since prior chemotherapy regimen include doxorubicin methotrexate catabolic steroid ( prevent nausea , vomit , fluid retention , hypersensitivity reaction ) No routine regular strenuous exercise ( 90 minute per day 6 days/week OR 120 minute per day 4 days/week ) Hormone receptor status : Estrogen progesterone receptor negative OR Estrogen progesterone receptor positive PATIENT CHARACTERISTICS : Age : Any age Sex : Female Menopausal status : Postmenopausal ( diagnosis OR chemotherapyinduced ) No spontaneous menses 6 month increase folliclestimulating hormone decrease estradiol Performance status : Ambulatory Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No cardiac problem would preclude exercise No unstable angina Pulmonary : No respiratory problem would preclude exercise No chronic obstructive pulmonary disease No oxygen dependence Other : No endocrine disease ( e.g. , parathyroid hormone disorder ) would accelerate bone turnover loss No musculoskeletal problem disease would preclude exercise ( e.g. , movementlimiting arthritis , muscular dystrophy , chronic fatigue syndrome ) No know cognitive psychiatric disorder would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior adjuvant neoadjuvant chemotherapy allow No concurrent chemotherapy Endocrine therapy : See Disease Characteristics No concurrent tamoxifen Radiotherapy : Prior adjuvant radiotherapy chemotherapy allow No concurrent radiotherapy Surgery : Not specify Other : No concurrent bisphosphonates</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>menopausal symptom</keyword>
</DOC>